# M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

> **NCT06421935** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 141 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** M9466
- **DRUG:** Tuvusertib
- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone/Prednisolone

## Key facts

- **NCT ID:** NCT06421935
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-07
- **Primary completion:** 2027-02-22
- **Final completion:** 2027-02-22
- **Target enrollment:** 141 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06421935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06421935, "M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06421935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*